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Despite being challenging, delivery of eﬀective nursing care to patients with acute intermittent porphyria is a matter of utmost
importance. In this paper, the diversity of symptoms and the diﬃcult diagnosis of this condition are emphasized, and details
concerning the treatment of this disorder in the intensive care unit are presented. We believe that acute intermittent porphyria
should be borne in mind during performance of diﬀerential diagnosis of neurological, psychiatric, and gastroenterological
disorders on patients whose routine investigation tests are normal, especially when precipitating factors exist. Intensive care
measures and a multidisciplinary team approach are essential.
1.Introduction
Acute intermittent porphyria (AIP) is an autosomal dom-
inant disorder caused by deﬁciency of porphobilinogen
deaminase (PBGD), which is involved in the hepatic heme
biosynthesis [1]. Decreased PBGD activity leads to ele-
vated urine levels of porphyrin precursors, namely, delta-
aminolevulinic acid (ALA) and porphobilinogen (PBG),
which can be evidenced by the Watson-Schwartz test [2].
There are three autosomal dominant acute porphyrias:
AIP, variegate porphyria, and hereditary coproporphyria.
Symptomatic AIP prevalence is 2 to 3 cases per 100,000
persons per year [3].
Porphyria attacks can be triggered by environmental
factors, reduced calorie intake [4], medications (barbiturate,
calcium channel blockers, antibiotics, antifungals, and hor-
mones) [5], large alcohol intake, nicotine abuse, infection,
surgery, or psychological disorder. Endocrine factors and
steroid hormones may also be the cause of attacks.
The most frequent clinical manifestation of acute attacks
include vomiting, hypertension and tachycardia [6], acute
abdominal pain (incidence estimated at 85%–95%) [7], and
peripheral neuropathy with muscle weakness (42%–68%).
Respiratory failure is less common and less known (9%–
20%). The exact mechanism through which these signs and
symptoms occur remains unknown [8].
Treatment of this condition consists in eliminating the
precipitating factors, avoiding drugs that may trigger a crisis,
and treating possible infections. High-carbohydrate diet,
glucose infusion, or hematin infusion can also be prescribed.
Despite being challenging, eﬀective nursing care delivery
to patients with acute intermittent porphyria is a matter of
utmost importance. In the present paper, the diversity of
symptoms and the diﬃc u l td i a g n o s i so ft h i sc o n d i t i o na r e
emphasized, and details concerning the treatment of this
disorder in the intensive care unit using a multidisciplinary
approach are presented.2 Critical Care Research and Practice
2.CasesDescription
2.1. Patient 1. A white female patient aged 24 years and with
afamilyhistoryofAIPwasadmittedtotheintensivecareunit
(ICU)complainingofabdominalpainthathadbeenongoing
for the ﬁve previous months. She had been initially treated
with proton pump inhibitors and antispasmodic medication
in her hometown. Over the previous three months she
had evolved with diarrhea, vomiting, and progressive ﬂaccid
tetraparesis. Her condition had worsened over the previous
15 days, with involvement of respiratory muscles and need
for mechanical ventilation. Physical examination revealed a
conscious patient that responded with movements of the
headonly.ShepresentedwithaGlasgowcomascaleof8,ﬂac-
cid tetraplegia, facial hemiparesi s ,a n dh y p o g l o s s a lp a r a l y s i s ,
but was hemodynamically stable (with BP = 125/70mmHg
and heart rate of 110bpm). Chest auscultation showed dif-
fuse wheezes; heart and abdomen auscultation was normal.
The APACHE II score [9] was 20.
Blood lead level gave no evidence of heavy metal poi-
soning. Lumbar puncture with cerebrospinal ﬂuid analysis
showed absence of Guillain-Barre syndrome. On the basis
of the patient’s clinical and familial history, the presence of
AIPwasinvestigated,which includeddeterminationofdelta-
aminolevulinic acid (ALA) (39.6mg/g creatinine—normal
value: 4.5mg/g creatinine) and porphobilinogen (PBG)
(17.75mg/day—normal value: 3.5mg/day) upon admission
to the ICU. Electromyography results demonstrated the
presence of severe sensory motor axonal polyneuropathy.
On the basis of the clinical ﬁndings and complementary
examinations, a high-carbohydrate diet (400 to 450g/day)
was started, as recommended for AIP cases. Treatment with
hematin was only initiated later, due to the diﬃculty in
obtaining the drug, and it was maintained for 14 days.
During her stay in the ICU, the patient progressed
with symptoms of urinary tract infection and pneumonia
associated with mechanical ventilation. The patient was
dismissed from the ICU after a 107-day stay and discharged
from hospital 79 days later. On her last visit to the outpatient
clinic, she was capable of ambulating short distances. She
was able to carry out personal hygiene and feed herself with
assistance.
2.2. Patient 2. A 47-year-old male patient with a history of
alcoholism was admitted to the ICU with initial symptoms
of diﬀuse strong abdominal pain that had started 15 days
previously. Approximately 5 days prior to admission, the
patient had presented with trembling and visual hallucina-
tions, as well as pain and weakness in the inferior limbs. He
was initially treated for alcohol abstinence in his hometown.
There was a sharp increase in muscle weakness, which
demanded orotracheal intubation, sedation, and invasive
mechanical ventilation three days after ICU admission.
Physical examination revealed a conscious patient with
periods of spatial and temporal disorientation. His Glasgow
coma scale was 14, and the respiratory rate was 28bpm,
aided by accessory muscles, BP = 188/96mmHg, heart rate
= 138bpm. Respiratory auscultation demonstrated diﬀuse
wheezes; heart and abdomen auscultation was normal. The
APACHE II score was 17.
Blood lead level gave no evidence of heavy metal poi-
soning. Lumbar puncture with cerebrospinal ﬂuid analysis
showed absence of Guillain-Barre syndrome. PCR tests for
enterovirus, Epstein-Barr virus,cytomegalovirus, and herpes
simplex viruses were negative. Serology for HIV was also
negative. The computed tomography scan was normal. The
presence of AIP was investigated, which included dosage
of delta-aminolevulinic acid (ALA) levels on the second
and sixth day after ICU admission (17.8 and 28.5mg/day,
respectively—normal range: 1.3 to 7mg/day) and determi-
nation ofporphobilinogen (PBG) levelson the second day of
ICU stay (2.52mg/daynormal range: 0.0 to 2mg/day). The
Erlich test was positive, and hyponatremia persisted during
the ICU stay. Electromyography results revealed the presence
of sensory motor axonal polyneuropathy and asymmetric
neuropathy with signs of acute and chronic axonal loss.
On the basis of the clinical ﬁndings and complementary
examinations, a high-carbohydrate diet (400 to 450g/day)
was started, as recommended for AIP cases. Treatment with
hematin was only initiated after 20 days of ICU admission,
due to the diﬃculty in obtaining the drug, and it was
maintained for 9 days.
The patient was discharged from the ICU after a 54-day
stay and was discharged from hospital 20 days later. He was
breathing spontaneously, but presented motor deﬁcit and
diﬃculty in ambulating.
2.3. Patient 3. A male patient aged 31 years was admitted
to the ICU with a one-month history of urine retention
and constipation accompanied by abdominal pain and famiy
history of similar cases, but with no conﬁrmed diagnosis.
The patient had spent twenty days at an ICU in his
hometown, where hetested positive forthe Erlich test.Deter-
mination of delta-aminolevulinic acid (ALA) (32mg/day—
normal range: 1.3 to 7mg/day) and porphobilinogen (PBG)
(2.4mg/day—normal range: 0.0 to 2mg/day) levels was also
performed at his hometown, where AIP was suspected. After
a few days, the patient presented with weakening of the
inferior limbs. After another day, he presented tetraplegia
without sensitivity loss, hoarseness, dysphagia, and diplopia.
The patient underwent tracheostomy and mechanical venti-
lation due to globally reduced muscle strength.
Physical examination at the ICU revealed that the patient
wasawakeandconscious,andherespondedtoverbalstimuli.
His Glasgow coma scale was 10,BP = 140/80mmHg, and HB
= 98bpm. Heart, respiratory, and abdomen auscultation was
normal. The APACHE II score was 10.
Electromyography revealed a normal axonal pattern with
associated denervation of severe intensity. Lead dosage was
normal.
On the basis of the clinical ﬁndings and complementary
examinations, a high-carbohydrate diet (400 to 450g/day)
was started, as recommended for AIP cases. Treatment with
hematin was only initiated after 20 days of ICU admission,
due to the diﬃculty in obtaining the drug, and it was
maintained for 8 days.Critical Care Research and Practice 3
The patient was discharged from the ICU after a 17-
day stay, although he was under mechanical ventilation
with Bi-level Positive Airway Pressure (BIPAP), and he was
discharged from hospital 33 days later.
On his last visit to the outpatient clinic, he was still
tracheostomized. He was being assisted by a nurse, a phys-
iotherapist, and a phonoaudiologist, was being fed orally,
and presented signiﬁcant clinicalimprovement,being able to
ambulate without assistance.
3.Discussion
Under normal conditions, enzyme deﬁciency alone is not
suﬃcient to trigger a porphyria attack. Generally, the
presence of other precipitating factors is necessary to induce
appearance of symptoms. Around 80% of the people with
deﬁciency of enzymatic activity never present any symptoms
(latent AIP), whereas others experience only occasional,
slight symptoms [8].
The clinical history of AIP varies widely and shares many
symptoms andsigns commontootherdisorders, as observed
in the three cases reported here. Therefore, diagnosis is
based on laboratory criteria such as elevated excretion of
the porphyrin precursors ALA and PBG in the urine [10].
Accumulation of these precursors in the urine may change
the urine color after sun exposure, from yellowish to dark
red or brown, and occasionally purple. From a laboratory
viewpoint, a largely elevated PBG level in 24h urine is a
diagnosis of acute porphyria.
Of the three reported cases, two presented two signs and
symptoms of the disease that is, abdominal pain and high
blood pressure [11]. The three cases involved respiratory
failure that demanded mechanical ventilation. In case 1, the
triggering factor was not identiﬁed; alcohol intake was the
probable cause of the porphyria attack in case 2; signiﬁcant
stress factors within the family setting were the reason for
the crisis in case 3. Attention must be given to abdominal
pain symptoms in unusual attacks in critical patients, and
AIP should be suspected. When analyzed in isolation, the
patients’ symptoms may mimic several disorders of the
digestive system, so a high level of suspicion is mandatory.
In this sense, diagnosing porphyria is a diﬃcult task that
on many occasions is accomplished only after several attacks
of the disease. In an early phase, AIP may be hypothesized
and early diagnosed when there is a family history of the
condition, which was the case of patient 1.
Treatment of AIP consists in the management of the
symptoms with safe medications, discontinued use of
porphyrinogenic drugs, elevated carbohydrate supply, and
hematin infusion. The latter drug inhibits the action of
the ﬁrst enzyme involved in the heme synthetic pathway,
thereby blocking porphyrin production and accumulation.
This therapy was successfully applied in the three cases
reported herein.
Because AIP diagnosis requires several complementary
analyses and the therapeutic protocols incur extremely high
costs, such services are only available in major hospitals of
large cities in Brazil. The access to early diagnosis is diﬃcult
for most individuals living outside the metropolitan areas.
Early AIP diagnosis and prompt prescription of speciﬁc
therapies along with implementation of a family assistance
program are extremely important for the successful manage-
ment of this condition [12].
Because AIP is little known to the lay population and
since its repercussions are potentially fatal, an interdisci-
plinary approach that ensures adequate medical, nursing,
andpsychotherapeuticsupportiscrucialduringcaredelivery
to AIP patients. In the present cases, the multiprofessional
team working at our ICU designed collaborative strategies
for patient treatment. The extremely rare acute occurrence
of this disease implies that most of the patients and
relatives do not have any knowledge of this pathology or its
evolution,which results in fear and insecurity. Therefore, the
multiprofessional staﬀ must be prepared to give information
about this illness and its progression.
Our experience showed that it is useful to initially
inform relatives of the reasons for patient transfer to the
ICU and explain their symptoms, especially those related to
dependence and discomfort, such as pain and respiratory
failure. Psychological support to the relatives is also an
important therapeutic tool, since it promotes closer and
more positive interactions among relatives, the patient,
and the multiprofessional team, thus favoring formation of
therapeutic alliances.
One of the aims of the nursing team during the man-
agement of AIP patients is to design an action plan that will
detectproblemsandestablishinterventionsthat will improve
patient conditions (nursing assistance systematization). AIP
may result in patient inability to maintain spontaneous
breathing, which will demand constant monitoring of the
vital signs and breathing pattern.
Moreover, many conditions, including AIP, lead to
impaired physical mobility, not to mention that the patient
may be at risk of developing pressure ulcers. Therefore,
it is essential that every two hours the patient is assisted
with changing positions, in order to prevent decubitus.
Patient mobilization could also be fostered by helping
the individuals to leave the bed or even by taking them
on wheelchair rides outside the ICU environment. These
procedures can be organized with the collaboration of the
entire multiprofessional team. The team must also be ready
to detect signs of fear and anxiety that are commonly related
to the sudden appearance of symptoms and the loss of
functional abilities.
Although most AIP patients rarely experience an attack,
other diseases such as chronic renal failure, systemic arte-
rial hypertension, and hepatocarcinoma may occur during
porphyria progression [8]. Prevention of new attacks is
as important as the early AIP diagnosis and treatment,
therebyavoidingcomplications.Therefore, medicalfollowup
associated with such simple measures as attention to the diet
avoidance of porphyrinogenic drugs, alcohol, and tobacco
and stress relief are mandatory. It is also important that all
the AIP patients’ relatives are evaluated, even if they are
asymptomatic, in order to verify whether the genetic defect
[13, 14] is present and, if so, to start prevention. Finally, a
multidisciplinary evaluation involving the neurology staﬀ is4 Critical Care Research and Practice
important, so that preventive measures can be taken early,
thereby avoiding patient hospitalization in the ICU. Also,
patients should be discharged from hospital as soon as
possible, in order to prevent complications related to long
ICU stay, such as hospital infections. Patient followup at
h o m ev i ah o m ec a r es h o u l db ee n c o u r a g e d .
4.Conclusion
We believe that intensivists should suspect AIP in the dif-
ferential diagnosisofneurological,psychiatric, and gastroen-
terologic disorders in the case of patients whose routine tests
are normal, especially when precipitating factors exist. ICU
support measures along with the work ofa multiprofessional
staﬀ are essential.
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